Metformin Hydrochloride Extended-Release Tablets USP 750 + GLUCOPHAGE®XR tablet 750 mg

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Fasting

Conditions

Fasting

Trial Timeline

Dec 1, 2012 → Feb 1, 2013

About Metformin Hydrochloride Extended-Release Tablets USP 750 + GLUCOPHAGE®XR tablet 750 mg

Metformin Hydrochloride Extended-Release Tablets USP 750 + GLUCOPHAGE®XR tablet 750 mg is a phase 1 stage product being developed by Ipca Laboratories for Fasting. The current trial status is completed. This product is registered under clinical trial identifier NCT01831674. Target conditions include Fasting.

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01831674Phase 1Completed

Competing Products

20 competing products in Fasting

See all competitors
ProductCompanyStageHype Score
OlanzapineDr. Reddy's LaboratoriesPhase 1
26
Terbinafine Hydrochloride Tablets, 250 mgDr. Reddy's LaboratoriesPhase 1
26
Amlodipine Besylate/Benazepril HClDr. Reddy's LaboratoriesPhase 1
26
ClopidogrelDr. Reddy's LaboratoriesPhase 1
26
CIPRO®XRDr. Reddy's LaboratoriesPhase 1
26
Mycophenolate MofetilDr. Reddy's LaboratoriesPhase 1
26
ClopidogrelDr. Reddy's LaboratoriesPhase 1
26
Levocetirizine DiHClDr. Reddy's LaboratoriesPhase 1
26
Olanzapine OD Tablets 5 mgDr. Reddy's LaboratoriesPhase 1
26
Pantoprazole SodiumDr. Reddy's LaboratoriesPhase 1
26
DesloratadineDr. Reddy's LaboratoriesPhase 1
26
ReminylDr. Reddy's LaboratoriesPhase 1
26
Lamotrigine Tablets 25 mg + LamotrigineIpca LaboratoriesPhase 1
29
Metformin Hydrochloride Extended-Release Tablets USP 750 mg + GLUCOPHAGE®XRIpca LaboratoriesPhase 1
29
Ondansetron Tablets USP 8 mg + Ondansetron HydrochlorideIpca LaboratoriesPhase 1
29
Quetiapine Fumarate Tablets 25 mg + Quetiapine FumarateIpca LaboratoriesPhase 1
29
Metoprolol Succinate ER Tablets 50 mg + 'TOPROL-XL®' ER Tablets 50 mgIpca LaboratoriesPhase 1
29
Etodolac Capsules USP 300 mg + EtodolacIpca LaboratoriesPhase 1
29
Risperidone Tablet 1 mg + RisperidoneIpca LaboratoriesPhase 1
29
Lisinopril and Hydrochlorothiazide Tablets (20+25) mg + Zestoretic® 20/25 lisinopril/hydrochlorothiazide TabletsIpca LaboratoriesPhase 1
29